Peng, J & Jordan, VC. (2006) Estrogen receptor pathways and breast cancer. In: Principles of Molecular Oncology, Third Edition. (Miquel H. Bronchud, MD, PhD, MaryAnn Foote, PhD, Guiseppe Giaccone, MD, PhD, Olufunmilayo Olopade, MD and Paul Workman, PhD (eds)) Humana Press NJ (in press).
Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC.
(2007) Role for HER2/neu and HER3 in fulvestrant -resistant breast cancer.
International Journal of Oncology 30:509-20
Abdelrahim M, Ariazi E, Kim K, Khan S, Barhoumi R, Burghardt R, Liu S, Hill D, Finnell R, Wlodarczyk B, Jordan VC, Safe S. (2006) 3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly active estrogen receptor alpha. Cancer Research. 66:2459-2467
Ariazi E, Lewis-Wambi JS, Gill SD, Pyle JR, Ariazi JL, Kim HR, Sharma CGN, Cordera F, Shupp HA, Li T, Jordan VC. (2006) Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant. Journal of Steroid Biochemistry and
Molecular Biology 102:128-38.
Ariazi EA, Ariazi JL, Cordera F, Jordan VC. (2006) Estrogen Receptors as Therapeutic Targets in Breast Cancer. Current Topics in Medicinal Chemistry 6:195-216
Ariazi EA, Jordan VC. (2006) Estrogen-related Receptors as Emerging Targets in Cancer and Metabolic Disorders. Current Topics in Medicinal Chemistry. 6:181-93
Ariazi EA, Kraus RJ, Farrell ML, Jordan VC and Mertz JE. (2006) Estrogen-related receptor α1's transcriptional activities are regulated in
part via the ErbB2 (HER2) signaling pathway. Molecular Cancer Research (in press).
Buzdar, A.U., Harvey, H.A. and Jordan, V.C. (2006) Estrogen, Antiestrogens and Aromatase Inhibitors. In Cancer Medicine 7th Ed. Kufe, Bast, Hait, Hong, Pollock, Weicheselbaum, Holland, Frei (eds) BC Decker, Inc. Hamiton, London pp 828-842.
Chatterton RT, Zujewski J, Mateo ET, Eng-Wong J, Jordan VC. (2006) Effect of raloxifene on salivary sex steroid concentrations in premenopausal women. Journal of Endocrinology 191:1-7.
Cordera F and Jordan, VC. (2006). Anti-hormonal therapy for breast and prostate cancer. In: Cancer Handbook, 2nd Edition (ed. Professor Malcolm R. Alison) John Wiley & Sons, London, UK (in press).
Cordera F and Jordan, VC. (2006). Steroid Receptors and their role in the biology and control of breast cancer. In: Seminars in Oncology Vol. 33 (eds. Drs. Gloria Morris and Kendra Feeney) W.B. Saunders, Philadelphia, PA pp 631-641.
Jordan, V.C. (2006) Activated estrogens and antiestrogens: A 30 year journey with David Kupfer. Drug Metabolism Reviews (Memorial Issue) 38:
117-127.
Jordan,VC (2006) Improvements in tumor targeting, survivorship and chemoprevention pioneered by tamoxifen: a Personal Perspective. 20th
Anniversary Series Oncology 20:553-577.
Jordan VC (2006) When do we give systemic therapy for breast cancer: before or after surgery? Evidence Based Obstetrics and Gynecology 8:64-65.
Jordan, VC (2006) (Editorial) Pak your breast tumor and grow! Journal of the National Cancer Institute 98:657-659.
Jordan, VC (2006) Final Words: A Star is Born. Oncology 20:1126.
Jordan, VC (2006) (Commentary) The Science of SERMs: concept to clinical practice. Clinical Cancer Research 12:5010-5013.
Jordan, VC (2006) Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology 147:S269-276.
Jordan, VC (2006) (Interview) From the birth of tamoxifen to today. Clinical Updates in Breast Cancer. (Issue 4) 1:8-10.
Jordan, VC (2006) (Commentary) Beyond raloxifene for the prevention of osteoporosis and breast cancer. British Journal of Pharmacology 150:3-4.
Jordan, VC (2006) (Commentary) Optimizing endocrine approaches for the chemoprevention of breast cancer: beyond the study of tamoxifen and
raloxifene (STAR) trial. European Journal of Cancer 42:2909-2913.
Jordan, VC (2006) (Commentary) SERMs: meeting the promise of multifunctional medicines. Journal of National Cancer Institute (in press).
Jordan VC. (2006) Chemoprevention of breast cancer with selective oestrogen receptor modulators. Nature Reviews Cancer 7:46-53.
Jordan, VC. (2006) Case Histories: Tamoxifen. In: Comprehensive Medicinal Chemistry II, Volume 8 (eds. John Taylor and David Triggle) Elsevier
Limited, Oxford, UK. pp 83-102.
Jordan, VC. (2006) A personal account of the chemoprevention of breast cancer: Possible or not possible? In: Principles of Molecular Oncology,
Third Edition. (Miquel H. Bronchud, MD, PhD, MaryAnn Foote, PhD, Guiseppe Giaccone, MD, PhD, Olufunmilayo Olopade, MD and Paul Workman, PhD (eds)) Humana Press NJ (in press).
Jordan, VC and Brodie, AMH (2006) Development and evolution of targeted endocrine therapies for the treatment of breast cancer. (Charles F.
Kettering Prize, General Motors Cancer Research Foundation) Steroids 72:7-25.
Kelloff GJ, Lippman SM, Dannenberg, AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lee JJ, Dubinett SM, Engstrom PF, Meyskens (jr) FL, Ransohoff DF, Hawk ET, Levin B, Nelson WG, Hong WK (AACR Cancer Prevention Task Force). (2006) Progress in chemoprevention drug development: The promise of molecular biomarkers for cancer prevention and treatment and prevention of intraepithelial neoplasia (IEN) A plan to move forward. Clinical Cancer Research, 12:3661-3697.
Lewis, JS and Jordan, VC. (2006) Case Histories: Raloxifene. In: Comprehensive Medicinal Chemistry II, Volume 8 (eds. John Taylor and David
Triggle) Elsevier Limited, Oxford, UK 103-121.
Lewis-Wambi J, & Jordan VC. (2006) Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Breast Disease 24:93-105.
Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC. (2006) Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivty in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. International Journal of Oncology
29:1237-46.
Liu S, Abdelrahim M, Khan S, Ariazi E, Jordan VC, Safe S. (2006) Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in
MCF-7 breast cancer cells. Biological Chemistry, 287:1209-1213.
Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM. (2006) Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Research 66:7176-7184.
O'Regan, R. M., Osipo, C., Ariazi, E., Lee, E. S., Meeke, K., Morris, C., Bertucci, A., Sarker, M. A., Grigg, R., and Jordan, V. C. Development and
therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clinical Cancer Research, 12: 2255-2263, 2006
Schafer JM, Jordan VC. (2006) Models of hormone resistance in vitro and in vivo. In: Methods in Molecular Medicine (eds. Susan A. Brooks and Adrian Harris) Humana Press, Totowa, New Jersey 120:453-64.
Vogel, VG, Costantino, JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers, TB, Fehrenbacher L, Pajon (jr) ER, Wade JL III, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. (2006) The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial. Journal of the American Medical Association 23:2727-41.